News
CGEN
2.645
+8.40%
0.205
Weekly Report: what happened at CGEN last week (0810-0814)?
Weekly Report · 3d ago
Weekly Report: what happened at CGEN last week (0803-0807)?
Weekly Report · 08/10 10:24
Compugen: Better Runway Ahead Of MAIA
Seeking Alpha · 08/07 03:59
Compugen Earnings Call Highlights Long-Term Biotech Upside
TipRanks · 08/05 00:47
H.C. Wainwright Keeps Their Buy Rating on Compugen (CGEN)
TipRanks · 08/04 08:57
Compugen Sets September 10, 2026 Annual Meeting, Details Board, Pay and Auditor Votes
TipRanks · 08/03 12:29
Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates
NASDAQ · 08/03 12:05
Compugen Posts Q2 2026 Results as Key Cancer Immunotherapy Trials Advance
TipRanks · 08/03 11:27
Compugen reports Q2 EPS (7c), consensus (9c)
TipRanks · 08/03 11:10
Compugen Q2 EPS $(0.07), Inline, Sales $2.602M Beat $1.606M Estimate
Benzinga · 08/03 11:01
Compugen Reports Second Quarter 2026 Results
PR Newswire · 08/03 11:00
Weekly Report: what happened at CGEN last week (0727-0731)?
Weekly Report · 08/03 10:24
Here are the major earnings before the open Monday
Seeking Alpha · 08/02 22:00
Compugen Q2 2026 Earnings Preview
Seeking Alpha · 07/31 15:01
Weekly Report: what happened at CGEN last week (0720-0724)?
Weekly Report · 07/27 10:28
Catalyst Watch: Tech majors report, FOMC, Jersey Mike's IPO and more oil anxiety
Seeking Alpha · 07/24 19:00
Analysts Offer Insights on Healthcare Companies: Compugen (CGEN), Telix Pharmaceuticals (OtherTLPPF) and Sarepta Therapeutics (SRPT)
TipRanks · 07/21 22:00
Compugen to Participate in BTIG Biotechnology Conference 2026
PR Newswire · 07/21 11:00
Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026
PR Newswire · 07/20 11:00
Weekly Report: what happened at CGEN last week (0713-0717)?
Weekly Report · 07/20 10:24
More
Webull provides a variety of real-time CGEN stock news. You can receive the latest news about Compugen through multiple platforms. This information may help you make smarter investment decisions.
About CGEN
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.